PulseAugur
EN
LIVE 20:20:21

AbbVie buys Apogee for $10.9B; AI startup Cadence raises $100M

By PulseAugur Editorial · [1 sources] ·

AbbVie has acquired Apogee Therapeutics for $10.9 billion to bolster its immunology franchise with Apogee's lead drug, zumilokibart, which shows promise in treating autoimmune conditions. Separately, the AI startup Cadence has raised $100 million at a $1.2 billion valuation, led by Spark Capital. Cadence utilizes AI agents to monitor patients with chronic diseases, aiming to improve health outcomes and reduce healthcare costs, reportedly saving Medicare over $2 million weekly. AI

IMPACT AI's role in chronic disease management is validated, potentially reducing healthcare costs and improving patient outcomes.

RANK_REASON The cluster contains a major acquisition by a large pharmaceutical company and a significant funding round for an AI-focused health tech startup. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on Forbes — Innovation →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

AbbVie buys Apogee for $10.9B; AI startup Cadence raises $100M

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
The cluster contains a major acquisition by a large pharmaceutical company and a significant funding round for an AI-focused health tech startup. [lever_c_demoted from significant: ic=1 ai=0.7]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
94 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Forbes — Innovation TIER_1 English(EN) · Alex Knapp, Forbes Staff ·

    AbbVie’s $11 Billion Immunology Bet

    In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more.

RELATED ENTITIES

RELATED TOPICS